Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial
Celis-Morales, Carlos, Marsaux, Cyril F.M., Livingstone, Katherine M., Navas-Carretero, Santiago, San-Cristobal, Rodrigo, Fallaize, Rosalind, Macready, Anna L., O'Donovan, Clare, Woolhead, Clara, Forster, Hannah, Kolossa, Silvia, Daniel, Hannelore, Moschonis, George, Mavrogianni, Christina, Manios, Yannis, Surwillo, Agnieszka, Traczyk, Iwona, Drevon, Christian A., Grimaldi, Keith, Bouwman, Jildau, Gibney, Mike J., Walsh, Marianne C., Gibney, Eileen R., Brennan, Lorraine, Lovegrove, Julie A., Martinez, J. Alfredo, Saris, Wim H.M. and Mathers, John C. 2017, Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial, American journal of clinical nutrition, vol. 105, no. 5, pp. 1204-1213, doi: 10.3945/ajcn.116.145680.
Attached Files
Name
Description
MIMEType
Size
Downloads
Title
Can genetic-based advice help you lose weight? Findings from the Food4Me European randomized controlled trial
Background: There has been limited evidence about whether genotype-tailored advice provides extra benefits in reducing obesity-related traits compared with the benefits of conventional one-size-fits-all advice.Objective: We determined whether the disclosure of information on fat-mass and obesity-associated (FTO) genotype risk had a greater effect on a reduction of obesity-related traits in risk carriers than in nonrisk carriers across different levels of personalized nutrition.Design: A total of 683 participants (women: 51%; age range: 18-73 y) from the Food4Me randomized controlled trial were included in this analysis. Participants were randomly assigned to 4 intervention arms as follows: level 0, control group; level 1, dietary group; level 2, phenotype group; and level 3, genetic group. FTO (single nucleotide polymorphism rs9939609) was genotyped at baseline in all participants, but only subjects who were randomly assigned to level 3 were informed about their genotypes. Level 3 participants were stratified into risk carriers (AA/AT) and nonrisk carriers (TT) of the FTO gene for analyses. Height, weight, and waist circumference (WC) were self-measured and reported at baseline and months 3 and 6.Results: Changes in adiposity markers were greater in participants who were informed that they carried the FTO risk allele (level 3 AT/AA carriers) than in the nonpersonalized group (level 0) but not in the other personalized groups (level 1 and 2). Mean reductions in weight and WC at month 6 were greater for FTO risk carriers than for noncarriers in the level 3 group [-2.28 kg (95% CI: -3.06, -1.48 kg) compared with -1.99 kg (-2.19, -0.19 kg), respectively (P = 0.037); and -4.34 cm (-5.63, -3.08 cm) compared with -1.99 cm (-4.04, -0.05 cm), respectively, (P = 0.048)].Conclusions: There are greater body weight and WC reductions in risk carriers than in nonrisk carriers of the FTO gene. This trial was registered at clinicaltrials.gov as NCT01530139.
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO.
If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.
Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.
orcid.org/0000-0002-9682-7541
Cited 
Cited 